| 1 | learn more image description | | | | | | | 3 | 0.94% |
| 2 | is a humanized monoclonal | | | | | | | 2 | 0.63% |
| 3 | stopping cancer requires new | | | | | | | 2 | 0.63% |
| 4 | description stopping cancer requires | | | | | | | 2 | 0.63% |
| 5 | 2024 leap therapeutics reports | | | | | | | 2 | 0.63% |
| 6 | 2024 leap therapeutics to | | | | | | | 2 | 0.63% |
| 7 | a humanized monoclonal antibody | | | | | | | 2 | 0.63% |
| 8 | advanced clinical candidate dkn01 | | | | | | | 1 | 0.31% |
| 9 | dkn01 is a humanized | | | | | | | 1 | 0.31% |
| 10 | candidate dkn01 is a | | | | | | | 1 | 0.31% |
| 11 | clinical candidate dkn01 is | | | | | | | 1 | 0.31% |
| 12 | leap therapeutics leap therapeutics | | | | | | | 1 | 0.31% |
| 13 | immunooncology therapeutics leap’s most | | | | | | | 1 | 0.31% |
| 14 | and immunooncology therapeutics leap’s | | | | | | | 1 | 0.31% |
| 15 | developing targeted and immunooncology | | | | | | | 1 | 0.31% |
| 16 | lptx is focused on | | | | | | | 1 | 0.31% |
| 17 | therapeutics nasdaq lptx is focused | | | | | | | 1 | 0.31% |
| 18 | targeted and immunooncology therapeutics | | | | | | | 1 | 0.31% |
| 19 | the dickkopf1 dkk1 protein | | | | | | | 1 | 0.31% |
| 20 | humanized monoclonal antibody targeting | | | | | | | 1 | 0.31% |
| 21 | targeting the dickkopf1 dkk1 | | | | | | | 1 | 0.31% |
| 22 | team leap therapeutics nasdaq lptx | | | | | | | 1 | 0.31% |
| 23 | dickkopf1 dkk1 protein dkn01 | | | | | | | 1 | 0.31% |
| 24 | dkk1 protein dkn01 is | | | | | | | 1 | 0.31% |
| 25 | protein dkn01 is being | | | | | | | 1 | 0.31% |
| 26 | dkn01 is being developed | | | | | | | 1 | 0.31% |
| 27 | is being developed in | | | | | | | 1 | 0.31% |
| 28 | developed in patients with | | | | | | | 1 | 0.31% |
| 29 | patients with esophagogastric gynecologic | | | | | | | 1 | 0.31% |
| 30 | with esophagogastric gynecologic and | | | | | | | 1 | 0.31% |
| 31 | esophagogastric gynecologic and colorectal | | | | | | | 1 | 0.31% |
| 32 | gynecologic and colorectal cancers | | | | | | | 1 | 0.31% |
| 33 | and colorectal cancers fl301 | | | | | | | 1 | 0.31% |
| 34 | leap therapeutics nasdaq lptx is | | | | | | | 1 | 0.31% |
| 35 | join our team leap | | | | | | | 1 | 0.31% |
| 36 | our team leap therapeutics nasdaq | | | | | | | 1 | 0.31% |
| 37 | study at the 2024 | | | | | | | 1 | 0.31% |
| 38 | financial results jan 16 | | | | | | | 1 | 0.31% |
| 39 | results jan 16 2024 | | | | | | | 1 | 0.31% |
| 40 | jan 16 2024 leap | | | | | | | 1 | 0.31% |